Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. HTZ
3. KBH
4. FDX
5. HON
6. HONA
7. HELP
8. GDYN
9. NKE
10. TTWO

Go back to Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

Aerie Pharma (AERI) PT Raised to $70 at Aegis Capital Following Phase III Trial

May 25, 2017 8:24 AM EDT

Aegis Capital raised its price target on Aerie Pharma (NASDAQ: AERI) to $70.00 (from $63.00) while maintaining a Buy rating. Aerie Pharmaceuticals announced positive 3-month top-line efficacy results from its pivotal phase III Mercury 2 trial for. Roclatan's 3-month efficacy results were positive across all 9 time... More